Ascendiant Capital Markets Raises Daxor (NASDAQ:DXR) Price Target to $24.75

Daxor (NASDAQ:DXR) had its price objective boosted by Ascendiant Capital Markets from $24.50 to $24.75 in a report issued on Monday, Marketbeat.com reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Daxor Stock Performance

NASDAQ:DXR opened at $9.14 on Monday. Daxor has a 12-month low of $7.11 and a 12-month high of $10.04. The stock’s fifty day simple moving average is $8.83 and its 200-day simple moving average is $8.95.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.